Viridian Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:VRDN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -73.33 M-92.65 M-75.37 M-84.61 M-23.75 M -276.39 M Cash from investing activities -62.91 M100.06 M75.72 M126.08 M-339.42 M -37.56 M Cash from financing activities 35.52 M9.21 M764 K10.86 M405.91 M 426.74 M Free cash flow -73.45 M-92.74 M-75.42 M-84.74 M-23.99 M -276.89 M

News

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN)

Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow (NASDAQ:VRDN) 2026-04-02

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment

Stifel reiterates Viridian Therapeutic stock rating on BLA review

Jefferies raises Viridian Therapeutic stock price target on trial progress

Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction